FHTX Foghorn Therapeutics

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Guggenheim Second Annual Healthcare Innovation Conference

  • Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET
  • Presenter: Adrian Gottschalk, President and Chief Executive Officer
  • Management will also participate in one-on-one meetings

Stifel 2025 Healthcare Conference

  • Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET
  • Presenter: Adrian Gottschalk, President and Chief Executive Officer
  • Management will also participate in one-on-one meetings

Jefferies 2025 London Healthcare Conference

  • Fireside Chat: Wednesday, November 19, 2025, at 10:30 a.m. GMT
  • Presenter: Adrian Gottschalk, President and Chief Executive Officer
  • Management will also participate in one-on-one meetings

A webcast of the available presentations can be accessed under “Events & Presentations” in the Investors section of the Company’s website, , and will be available for 90 days.

About Foghorn Therapeutics

Foghorn® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at  for more information on the Company, and follow us on  and .

Contact:

Karin Hellsvik, Foghorn Therapeutics Inc.



EN
03/11/2025

Underlying

FHTXFoghorn Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Foghorn Therapeutics

 PRESS RELEASE
Free
FHTX Foghorn Therape...

Foghorn Therapeutics to Participate in Three Upcoming Investor Confere...

Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and res...

November 3, 2025 1 EN
Wedbush Research
  • Wedbush Research
LOGN LOGITECH INTERNATIONAL S.A.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NCMI NATIONAL CINEMEDIA INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
BIIB BIOGEN INC.
AXTI AXT INC.
ARDX ARDELYX INC
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CVCO CAVCO INDUSTRIES INC.
ROKU ROKU INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
HEAR TURTLE BEACH CORP.
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
TVTX INC.
RZLT TRAVERE THERAPEUTICS INC
DFH REZOLUTE
PLTK DREAM FINDERS HOMES
RBLX PLAYTIKA HOLDING
FHTX ROBLOX
STX FOGHORN THERAPEUTICS
GFS SEAGATE TECHNOLOGY HLDGS PLC
EWTX GLOBALFOUNDRIES INC
EDGEWISE THERAPEUTICS INC
10/31/25 October 31, 2025 1 EN
Geoffrey Von Der Ahe ... (+3)
  • Geoffrey Von Der Ahe
  • Ritika Das
  • Robert Driscoll
FHTX FOGHORN THERAPEUTICS
10/30/25 October 30, 2025 1 EN
 PRESS RELEASE
Free
FHTX Foghorn Therape...

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective...

Foghorn Therapeutics Announces Updates for Selective ARID1B, Selective CBP and Selective EP300 Degrader Programs - Data presented at the TPD and Induced Proximity Summit demonstrate that novel Selective ARID1B degrader selectively binds and degrades ARID1B; potentially relevant in up to 5% of all solid tumors  - Selective CBP degrader is on track for non-GLP toxicology studies in Q4 2025 with potential in EP300-mutant cancers and in ER+ breast cancer; IND-ready in 2026 - Selective EP300 degrader demonstrates efficacy and favorable tolerability in preclinical models in hematological ma...

October 30, 2025 1 EN
 PRESS RELEASE
Free
FHTX Foghorn Therape...

Foghorn Therapeutics Announces Significant Progress for Selective ARID...

Foghorn Therapeutics Announces Significant Progress for Selective ARID1B Degrader at the 8th Annual TPD and Induced Proximity Summit Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDT CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced key development updates for its...

October 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch